Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmagen cz s.r.o., Česká republika - sunitinib - 44 - cytostatica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmevid s.r.o., slovensko - sunitinib - 44 - cytostatica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmevid s.r.o., slovensko - sunitinib - 44 - cytostatica

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmevid s.r.o., slovensko - sunitinib - 44 - cytostatica

European Union - Slovak - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostatné dermatologické prípravky - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

European Union - Slovak - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (ako fosfát) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastické činidlá - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi je indikovaný na liečbu dospelých pacientov s polycythaemia vera, ktorí sú odolné voči alebo netolerantné hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

European Union - Slovak - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - sunitinib - 44 - cytostatica

European Union - Slovak - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - kolorektálne novotvary - antineoplastic agents, protein kinase inhibitors - stivarga je označené ako monotherapy na liečbu dospelých pacientov s metastatickým kolorektálnym (crc), ktorí boli v minulosti liečení, alebo nie sú považované za kandidátov na, k dispozícii terapie - tieto zahŕňajú fluoropyrimidine založené na chemoterapiu, anti-vegf terapia a anti-egfr terapia;unresectable alebo metastatickým gastrointestinálne stromal nádory (podstatu), ktorí postúpili na alebo netolerujú pred zaobchádzanie s imatinib a sunitinib;hepatocellular karcinóm (hcc), ktorí boli predtým liečení sorafenib.

European Union - Slovak - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - karcinóm, obličková bunka - protein kinase inhibítory - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.